2022 Will Be A Test For Gilead, Starting with TROPiCS-2 Study Of Trodelvy

Gilead Highlights Oncology Ambitions In Q4

Even as magrolimab stumbled, the company remains optimistic about the rest of its pipeline, from potential pipeline-in-a-pill Trodelvy to an oral COVID-19 drug.

Overcoming challenges and crisis . Mixed media
Gilead touted its oncology pipeline in its fourth quarter/full year 2021 earnings • Source: Shutterstock

Gilead Sciences, Inc. started off the year stating at the J.P. Morgan Healthcare Conference that oncology will account for one-third of its revenues by 2030. The firm’s 2021 sales demonstrate that it is largely dependent on infectious disease, but management used the 1 February earnings call to highlight some near-term catalysts in oncology that will help the firm with its diversification efforts.

“Our 2022 plans include a significant increase in clinical development studies across our novel oncology portfolio,” CEO Daniel O’Day told the fourth quarter/full year 2021 earnings call. The company’s full year sales beat guidance and quarterly sales beat consensus despite falling short of the comparable period of 2020

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Copycats Compound Novo’s Wegovy Growth Problems

 

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By 

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By 

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

More from Business

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By 

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By 

The sector is continuing to show resilience despite financial and market challenges.